Effects of Add-on Ramelteon on Cognitive Impairment in Patients with Schizophrenia: An Open-label Pilot Trial.
10.9758/cpn.2014.12.3.215
- Author:
Yukihiko SHIRAYAMA
1
;
Michio TAKAHASHI
;
Masatoshi SUZUKI
;
Yoshiaki TSURUOKA
;
Koichi SATO
Author Information
1. Department of Psychiatry, Teikyo University Chiba Medical Center, Ichihara, Japan. shirayama@rapid.ocn.ne.jp
- Publication Type:Original Article
- Keywords:
Ramelteon;
Schizophrenia;
Verbal learning
- MeSH:
Gambling;
Humans;
Iowa;
Learning;
Memory Disorders;
Outpatients;
Schizophrenia*;
Stroop Test;
Verbal Learning;
Wisconsin
- From:Clinical Psychopharmacology and Neuroscience
2014;12(3):215-217
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: This open-label study examined the effects of ramelteon on cognitive functions in 10 outpatients with schizophrenia. METHODS: Ramelteon (8 mg/day) was administered to 10 patients with schizophrenia for six months. The verbal fluency test, Trail-Making Test, the Wisconsin Card Sorting Test, the Stroop Test, the Digit Span Distraction Test, Iowa Gambling Task, the Rey Auditory Verbal Learning Test were evaluated at baseline and 6 months after treatment with ramelteon. RESULTS: Ramelteon improved significantly the scores of Rey Auditory Verbal Learning Test. Additionally, ramelteon exerted improvements in the verbal fluency and Iowa Gambling Task in 4 patients. CONCLUSION: Ramelteon could be a potential therapeutic drug, in adjunctive treatment of learning and memory deficits seen in patients with schizophrenia.
